First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.

Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

Phase 2 findings support olutasidenib as a potentially “valuable” treatment option in IDH1-mutated acute myeloid leukemia.

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

Responses with SLS009 were reported at 60 mg once weekly and 30 mg twice weekly for patients with relapsed/refractory acute myeloid leukemia.

Data from the phase 2 AUGMENT-101 trial support the biologics license application for revumenib in patients with relapsed/refractory KMT2A-rearranged acute leukemia.